These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
166 related articles for article (PubMed ID: 31510981)
1. Costs and benefits of bevacizumab vial sharing for the treatment of retinal diseases. Sodré SL; Barbosa IAF; Pacheco IE; Ferreira FQT; David MA; Nascimento MA; Arieta CEL; Vasconcellos JPC BMC Public Health; 2019 Sep; 19(1):1252. PubMed ID: 31510981 [TBL] [Abstract][Full Text] [Related]
2. Intravitreal bevacizumab: safety of multiple doses from a single vial for consecutive patients. Ng DS; Kwok AK; Chan CW; Li WW Hong Kong Med J; 2012 Dec; 18(6):488-95. PubMed ID: 23223649 [TBL] [Abstract][Full Text] [Related]
3. [Budget impact of the incorporation of second-line drug treatment for diabetic macular edema in the Brazilian Unified National Health System from the perspective of the Minas Gerais State Health Department, Brazil]. Izidoro JB; Piazza T; Andrade EIG; Alvares-Teodoro J Cad Saude Publica; 2019 Aug; 35(8):e00145518. PubMed ID: 31460612 [TBL] [Abstract][Full Text] [Related]
4. Intraocular use of bevacizumab in India: An issue resolved? Kumar A; Tripathy K; Chawla R Natl Med J India; 2017; 30(6):345-347. PubMed ID: 30117450 [TBL] [Abstract][Full Text] [Related]
5. Intravitreal Bevacizumab: Indications And Complications. Jan S; Nazim M; Karim S; Hussain Z J Ayub Med Coll Abbottabad; 2016; 28(2):364-368. PubMed ID: 28718542 [TBL] [Abstract][Full Text] [Related]
6. Experience of New Brunswick ophthalmologists using intravitreal anti-vascular endothelial growth factor. Giberson M; Taylor V Can J Ophthalmol; 2015 Oct; 50(5):393-4. PubMed ID: 26455977 [No Abstract] [Full Text] [Related]
7. Profile of patients treated with intravitreal antiangiogenics in a Brazilian public service with high level of complexity. Rabelo IA; Soares MC; Torigoe AMS Arq Bras Oftalmol; 2023; 87(5):e20220119. PubMed ID: 39298727 [TBL] [Abstract][Full Text] [Related]
8. Trends of Anti-Vascular Endothelial Growth Factor Use in Ophthalmology Among Privately Insured and Medicare Advantage Patients. Parikh R; Ross JS; Sangaralingham LR; Adelman RA; Shah ND; Barkmeier AJ Ophthalmology; 2017 Mar; 124(3):352-358. PubMed ID: 27890437 [TBL] [Abstract][Full Text] [Related]
9. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Khan P; Khan L; Mondal P Indian J Ophthalmol; 2016 Sep; 64(9):694-696. PubMed ID: 27853027 [TBL] [Abstract][Full Text] [Related]
10. Comparison of Aflibercept, Bevacizumab, and Ranibizumab for Treatment of Diabetic Macular Edema: Extrapolation of Data to Clinical Practice. Heier JS; Bressler NM; Avery RL; Bakri SJ; Boyer DS; Brown DM; Dugel PU; Freund KB; Glassman AR; Kim JE; Martin DF; Pollack JS; Regillo CD; Rosenfeld PJ; Schachat AP; Wells JA; JAMA Ophthalmol; 2016 Jan; 134(1):95-9. PubMed ID: 26512939 [TBL] [Abstract][Full Text] [Related]
11. A Multinational Comparison of Anti-Vascular Endothelial Growth Factor Use: The United States, the United Kingdom, and Asia-Pacific. Parikh R; Pirakitikulr N; Chhablani J; Sakurada Y; Singh RP; Modi YS Ophthalmol Retina; 2019 Jan; 3(1):16-26. PubMed ID: 30935655 [TBL] [Abstract][Full Text] [Related]
12. Same-Day Bilateral Intravitreal Anti-Vascular Endothelial Growth Factor Injections: Experience of a Large Canadian Retina Center. Juncal VR; Francisconi CLM; Altomare F; Chow DR; Giavedoni LR; Muni RH; Berger AR; Wong DT Ophthalmologica; 2019; 242(1):1-7. PubMed ID: 30928983 [TBL] [Abstract][Full Text] [Related]
13. High Variation of Intravitreal Injection Rates and Medicare Anti-Vascular Endothelial Growth Factor Payments per Injection in the United States. Erie JC; Barkmeier AJ; Hodge DO; Mahr MA Ophthalmology; 2016 Jun; 123(6):1257-62. PubMed ID: 26976701 [TBL] [Abstract][Full Text] [Related]
14. Bilateral same-day intravitreal injections using a single vial and molecular bacterial screening for safety surveillance. Woo SJ; Han JM; Ahn J; Heo JW; Yu HG; Chung H; Song J; Park KU; Park KH Retina; 2012 Apr; 32(4):667-71. PubMed ID: 22307220 [TBL] [Abstract][Full Text] [Related]
15. THE OMAR STUDY: Comparison of Ozurdex and Triamcinolone Acetonide for Refractory Cystoid Macular Edema in Retinal Vein Occlusion. Ozkok A; Saleh OA; Sigford DK; Heroman JW; Schaal S Retina; 2015 Jul; 35(7):1393-400. PubMed ID: 25748280 [TBL] [Abstract][Full Text] [Related]
16. Beri S; Shandil A; Garg R Indian J Ophthalmol; 2017 Nov; 65(11):1166-1171. PubMed ID: 29133644 [TBL] [Abstract][Full Text] [Related]
17. Off-label use of bevacizumab in the treatment of retinal disease: ethical implications. Rohowetz LJ J Med Ethics; 2019 Oct; 45(10):668-672. PubMed ID: 31320407 [TBL] [Abstract][Full Text] [Related]
18. A longitudinal study to assess the frequency and cost of antivascular endothelial therapy, and inequalities in access, in England between 2005 and 2015. Hollingworth W; Jones T; Reeves BC; Peto T BMJ Open; 2017 Oct; 7(10):e018289. PubMed ID: 29061629 [TBL] [Abstract][Full Text] [Related]
19. The use of bevacizumab in pediatric retinal and choroidal disease: A review. Belin PJ; Lee AC; Greaves G; Kosoy J; Lieberman RM Eur J Ophthalmol; 2019 May; 29(3):338-347. PubMed ID: 30757919 [TBL] [Abstract][Full Text] [Related]
20. Evaluating cost savings in cytotoxic leftover management: A prospective study of vial sharing and dose rounding techniques in the Moroccan National Institute of Oncology. El Baraka S; Cherif Chefchaouni A; Bourdaime A; Ouedraogo JM; Shytry O; Belahcen MJ; Rahali Y J Oncol Pharm Pract; 2024 Oct; 30(7):1152-1159. PubMed ID: 37728162 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]